Experimental Ebola Drug Arrives In Liberia; Officials Decide How To Allocate Limited Supply

News outlets report on the arrival of an experimental Ebola drug in Liberia and discuss how the limited doses of the drug will be allocated.

Associated Press/New York Times: Liberia Gets Ebola Drug; Ponders Who Should Get It
“Liberian officials faced an excruciating choice Thursday: deciding which handful of Ebola patients will receive an experimental drug that could prove life-saving, ineffective or even harmful. ZMapp, the untested Ebola drug, arrived in the West African country late Wednesday. Assistant Health Minister Tolbert Nyenswah said three or four people would begin getting it Thursday. The government had previously said two doctors would receive the treatment, but it was unclear who else would…” (8/14).

Reuters: Consignment of experimental Ebola drug arrives in Liberia
“A consignment of experimental Ebola drugs arrived by plane in Liberia on Wednesday to treat two doctors suffering from the virus, which has killed more than 1,000 people across four West African countries…” (MacDougall, 8/14).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.